Page last updated: 2024-11-06

reserpic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Reserpic acid is a naturally occurring indole alkaloid that was first isolated from the roots of the Rauwolfia serpentina plant. It has been used in traditional medicine for centuries to treat a variety of ailments. Reserpic acid is a potent inhibitor of the vesicular monoamine transporter (VMAT), which is responsible for the transport of neurotransmitters such as dopamine, norepinephrine, and serotonin into synaptic vesicles. Reserpic acid has been shown to have a variety of pharmacological effects, including antihypertensive, antipsychotic, and sedative effects. It has also been shown to have anti-inflammatory and anti-tumor activities. Reserpic acid is no longer widely used clinically due to its potential side effects, such as depression and extrapyramidal symptoms. However, it remains an important research tool for studying the role of monoamines in the central nervous system. Reserpic acid is also being investigated for its potential therapeutic uses in conditions such as Parkinson's disease and Alzheimer's disease.'

reserpic acid: inhibitor of norepinephrine transport into chromaffin vesicle ghosts; RN given refers to (3beta,16beta,17alpha,18beta,20alpha)-isomer parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65747
CHEMBL ID411716
CHEBI ID46690
SCHEMBL ID571464
MeSH IDM0134580

Synonyms (34)

Synonym
BRD-K32755366-003-03-4
NCI60_041786
BSPBIO_001047
BPBIO1_001153
PRESTWICK3_000984
PRESTWICK2_000984
reserpic acid
3.beta., 18.beta.-hydroxy-11,17.alpha.-dimethoxy-
83-60-3
NSC81463 ,
nsc-81463
reserpinolic acid
yohimban-16-carboxylic acid,17-dimethoxy-, (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-
AB00514690
18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylic acid
CHEBI:46690 ,
(3beta,16beta,17alpha,18beta,20alpha)-18-hydroxy-11,17-dimethoxyyohimban-16-carboxylic acid
PRESTWICK1_000984
PRESTWICK0_000984
SPBIO_002948
CHEMBL411716 ,
nsc 81463
yohimban-16-carboxylic acid, 18-hydroxy-11,17-dimethoxy-, (3beta,16beta,17alpha,18beta,20alpha)-
3beta,20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-
k6l9w0qp1w ,
unii-k6l9w0qp1w
bdbm50374533
yohimban-16-carboxylic acid, 18-hydroxy-11,17-dimethoxy-, (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-
reserpic acid [mi]
SCHEMBL571464
DTXSID50232112
reserpinsaure
Q1690907
(1r,15s,17r,18r,19s,20s)-17-hydroxy-6,18-dimethoxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"We will compare the clinical efficacy of thunder-fire moxibustion combined with acupressure with pure thunder-fire moxibustion on Ocular muscle spasm using random control method."( Observation on the clinical effect of thunder-fire moxibustion combined with acupressure on ocular muscle spasm: A clinical randomized controlled trial.
Cao, YF; Cui, PL; Li, Q; Li, TJ; Li, Y; Liu, Y; Lü, YY; Ma, QY; Nian, JY; Wu, Y; Xu, YM; Yang, C; Yang, YX; Zhang, Y; Zheng, YH, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
yohimban alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Synaptic vesicular amine transporterBos taurus (cattle)Ki10.00000.00103.335010.0000AID321546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
response to potassium ionSynaptic vesicular amine transporterBos taurus (cattle)
xenobiotic transportSynaptic vesicular amine transporterBos taurus (cattle)
serotonin uptakeSynaptic vesicular amine transporterBos taurus (cattle)
dopamine uptakeSynaptic vesicular amine transporterBos taurus (cattle)
somato-dendritic dopamine secretionSynaptic vesicular amine transporterBos taurus (cattle)
proton transmembrane transportSynaptic vesicular amine transporterBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
monoamine:proton antiporter activitySynaptic vesicular amine transporterBos taurus (cattle)
xenobiotic transmembrane transporter activitySynaptic vesicular amine transporterBos taurus (cattle)
organic cyclic compound bindingSynaptic vesicular amine transporterBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
axonSynaptic vesicular amine transporterBos taurus (cattle)
dendriteSynaptic vesicular amine transporterBos taurus (cattle)
secretory granule membraneSynaptic vesicular amine transporterBos taurus (cattle)
synaptic vesicle membraneSynaptic vesicular amine transporterBos taurus (cattle)
chromaffin granuleSynaptic vesicular amine transporterBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID321546Inhibition of dopamine uptake at VMAT in bovine chromaffin granule ghosts2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Vesicular monoamine transporter substrate/inhibitor activity of MPTP/MPP+ derivatives: a structure-activity study.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's6 (60.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.44 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews2 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]